Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

BioCryst Pharmaceuticals Announces Presentation Of Forodesine Data At The 45th Annual Meeting Of The American Society Of Clinical Oncology
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced long-term data from a Phase 2 study of forodesine, the Company"s lead oncology compound, in patients with cutaneous T-cell lymphoma (CTCL). The data will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Orlando, Florida from May 29-June 2. Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase (PNP), a purine salvage pathway enzyme that is essential for the proliferation of T-cells and B-cells.
generic viagra online
Practice Nurses Pivotal To Easing Primary Care Pressure, Australia
Nurses play a key role in supporting general practice and giving people access to primary health care services, the Australian Practice Nurses Association (APNA) and Australian Nursing Federation (ANF) said after the release today of two reports on general practice and practice nurses in Australia.
News of the day
Diabetes Amputees Converge On London's O2 Arena To Campaign For Better Foot Services
Diabetes UK is today bringing together 100 people, including 20 diabetes amputees, at the "Body Worlds and Mirror of Time" exhibition at London"s O2 Arena for a photo call to highlight the fact that diabetes causes 100 amputations a week in the UK.
Diagnostics

Data Presented At The 5th International AIDS Society Conference Suggests Low Testosterone Frequently Goes Undetected In HIV-Positive Men

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, announced that new data from the two-part HYHYHI Study (Hypogonadal Hypotestosteronism in HIV-Seropositive Men) were presented as a poster today at the 5th International AIDS Society (IAS) Conference in Cape Town, South Africa. This retrospective chart review, supported by the Company, evaluated the challenges associated with diagnosing low testosterone in men with HIV/AIDS. The study also compared the difference in testosterone levels achieved after 12 months of treatment with either Testim® 1% (testosterone gel) or AndroGel®, two commonly used FDA-approved testosterone replacement products. Results from the study showed that when using the more sensitive Free Testosterone test (FT About the Study The HYHYHI study, designed and conducted by Dr. Blick, was a retrospective chart review of men with HIV/AIDS screened for Low T and treated with testosterone replacement therapy. Data were collected from two U.S. sites and included 400 men diagnosed with HIV/AIDS and screened for Low T, defined as Total T About Testim Testim is a proprietary, clear, topical gel containing 1% testosterone, the same type of hormone that is produced by the human body. When applied once-daily to the upper arms and shoulders, clinical studies have shown that Testim will restore and maintain testosterone levels. Once Testim is absorbed through the skin, it enters the bloodstream and helps return testosterone to normal levels. The efficacy of Testim has been demonstrated in 16 clinical studies involving approximately 1,800 patients, including the largest placebo-controlled study ever conducted to evaluate the benefits and risks of testosterone replacement therapy. Auxilium estimates that approximately 76 million tubes, or daily applications, of Testim have been used since the product was launched in 2003. For information regarding the safety and use of Testim, please see the prescribing information at http://www.testim.com. Auxilium Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009